Comparative analysis of a novel next-generation sequencing-based IGH clonality assay for measurable residual disease detection in pediatric B-cell acute lymphoblastic leukemia patients.

• Tác giả: Duck Cho, Hee Young Ju, Hee-Jin Kim, Hyun-Young Kim, Ji Won Lee, Min-Seung Park, Keon Hee Yoo
• Ngôn ngữ: eng
• Ký hiệu phân loại: 335.437 Comparative studies
• Thông tin xuất bản: England : Pediatric hematology and oncology , 2025
• Bộ sưu tập: NCBI
• ID: 218770

Tóm tắt

 Measurable residual disease (MRD) is critical in guiding therapeutic strategies for B-cell acute lymphoblastic leukemia (B-ALL). This study evaluated the performance of a novel next-generation sequencing-based Celemics IGH assay (CM-IGH
  Celemics, Seoul, Korea) compared with the LymphoTrack